Intelligence · Patents
Patents expiring in 2038
Annual patent cliff calendar for 2038 — US pharmaceutical patents by expiration date.
- Patents
- 1,509
Quick answer
1,509 indexed pharmaceutical patents have expiration dates in 2038. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9949963
Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
granted -
US 9951002
Ionizable cationic lipid for RNA delivery
granted -
US 9950002
Nanoparticles/theranostic vehicles
granted -
US 9949927
Bis-polymer lipid-peptide conjugates and nanoparticles thereof
granted -
US 9949484
Antimicrobial polyurethane materials and methods of forming and using same
granted -
US 9957305
Anti-C. difficile toxin antibodies and associated methods
granted -
US 9957327
Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
granted -
US 9956215
Methods of treating cancer with farnesyltransferase inhibitors
granted -
US 9956282
Bacterial compositions and methods of use thereof for treatment of immune system disorders
granted -
US 9957259
Selective HDAC1 and HDAC2 inhibitors
granted -
US 9956172
Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
granted -
US 9956179
Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
granted -
US 9957501
Nuclease-mediated regulation of gene expression
granted -
US 9957507
Compositions and methods for inhibiting expression of mutant EGFR gene
granted -
US 9956293
Targeted therapeutics
granted -
US 9957504
Compositions and methods for modulating apolipoprotein (a) expression
granted -
US 9957486
Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
granted -
US 9957329
Factor XII inhibitors for the treatment of neurological inflammatory disorders
granted -
US 9957324
Anti-FLT-1 antibodies in treating duchenne muscular dystrophy
granted -
US 9957526
Delivery methods and compositions for nuclease-mediated genome engineering
granted -
US 9957292
Compositions and methods for modulating angiopoietin-like 3 expression
granted -
US 9957281
Benzodiazepine derivatives as RSV inhibitors
granted -
US 9957251
Heterocyclic compound
granted -
US 9957214
Multifunctional radical quenchers
granted -
US 9956216
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted -
US 9956278
Multivalent meningococcal conjugates and methods for preparing conjugates
granted -
US 9956247
Method of treating lysosomal storage diseases
granted -
US 9956267
Method of treating skeletal dysplasias using vessel dilator
granted -
US 9956188
Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
granted -
US 9956178
Methods for delivering insulin preparations into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 9957569
Recurrent gene fusions in prostate cancer
granted -
US 9962377
Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
granted -
US 9962385
Methods and compositions for treating abnormal cell growth
granted -
US 9962366
Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
granted -
US 9962448
Compounds and methods for targeted immune system delivery
granted -
US 9962352
Creatine oral supplementation using creatine hydrochloride salt
granted -
US 9963478
Mannose derivatives for treating bacterial infections
granted -
US 9963700
GNAQ targeted dsRNA compositions and methods for inhibiting expression
granted -
US 9962363
Mast cell stabilizers treatment for systemic disorders
granted -
US 9963715
Methods and compositions for treatment of a genetic condition
granted -
US 9963504
Anti-CXCL13 antibodies and methods of using the same
granted -
US 9962432
Minimizing intestinal dysfunction
granted -
US 9963515
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
granted -
US 9963443
Radiolabeled compounds
granted -
US 9963699
Methods for modulating C9ORF72 expression
granted -
US 9962390
Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
granted -
US 9963450
A3 adenosine receptor agonists
granted -
US 9962449
MultiLigand agent for drug delivery
granted
Frequently asked questions
How many pharma patents expire in 2038?
1,509 published patents in our USPTO index have expiration dates falling in calendar year 2038.